22.05.2022, 2509 Zeichen
Marinomed: Austrian Marinomed Biotech AG announced the execution of a license agreement with Procter & Gamble Company (NYSE: PG), hereinafter referred to as "P&G", for the United States of America regarding the Carragelose® products of Marinomed, which are protected by various patents that cover the use of iota-carrageenan for the treatment of diseases caused by or associated with an infection by a respiratory virus. P&G will take the necessary steps to obtain regulatory approval for the commercialization of the Carragelose® products in the United States of America. Marinomed is responsible for the technology transfer, i.e., providing P&G with the data required for obtaining regulatory approval and the intellectual property rights (patents, know-how) in the form of a license for the commercialization of the Carragelose® products in the United States of America. Under the terms of the agreement and depending on the achievement of specified regulatory and commercial milestones, Marinomed is eligible to receive milestone payments as well as royalties on Carragelose® sales in the United States of America.
Marinomed Biotech: weekly performance:
Wolford: Bodywear company Wolford AG further postpones the publication of the audited annual financial statements as of 31 December 31 and the audited consolidated financial statements as of 31 December 2021. The audited annual financial statements and the audited consolidated financial statements are to be published no later than 17 June 2022. The Annual General Meeting for the 2021 financial year will be postponed. A new date will be announced as soon as possible. A positive EBITDA is expected for the 2021 financial year. The previously communicated outlook of a positive EBIT cannot be sustained.
Wolford: weekly performance:
Vienna Stock Exchange: Vienna ESG Segment enhances transparency in the growing offering of ESG bonds. The new rulebook with mandatory inclusion and follow-up obligations for sustainable bonds enters into force today. It is based on internationally established standards (Principles of the International Capital Market Association). A second party opinion is required from new issuers, and ongoing disclosures are strengthened. The "Vienna ESG Segment" offers more visibility to companies that raise funds for green or social projects and meet the strict listing and follow-up requirements.
ATX TR: weekly performance:
(From the 21st Austria weekly https://www.boerse-social.com/21staustria (20/05/2022)
kapitalmarkt-stimme.at daily voice 48/365: Nach dem Börsentag in Frankfurt ist vor dem Börsentag in Wien - Save the Date (8.3.)
Aktien auf dem Radar:RHI Magnesita, Rosenbauer, EuroTeleSites AG, Warimpex, Kapsch TrafficCom, Lenzing, OMV, Österreichische Post, ATX, ATX Prime, ATX TR, Andritz, Erste Group, Uniqa, voestalpine, VIG, Mayr-Melnhof, DO&CO, Porr, Rosgix, EVN, Cleen Energy, Frequentis, Gurktaler AG Stamm, Wiener Privatbank, Zumtobel, UBM, SW Umwelttechnik, Amag, Oberbank AG Stamm, RBI.
Croma
Croma Pharma® ist ein österreichisches Familienunternehmen mit Sitz in Leobendorf. Das Unternehmen ist auf die industrielle Fertigung von Hyaluronsäure-Spritzen spezialisiert und zählt in diesem Bereich europaweit zu den führenden Experten. Das Unternehmen setzt mit eigenen Marken auf die Wachstumssparte der minimalinvasiven ästhetischen Medizin.
>> Besuchen Sie 68 weitere Partner auf boerse-social.com/partner
Die Useletter "Morning Xpresso" und "Evening Xtrakt" heben sich deutlich von den gängigen Newslettern ab.
Beispiele ansehen bzw. kostenfrei anmelden. Wichtige Börse-Infos garantiert.
Newsletter abonnieren
Infos über neue Financial Literacy Audio Files für die Runplugged App
(kostenfrei downloaden über http://runplugged.com/spreadit)
per Newsletter erhalten